Trial reportBone marrow transplantation2013
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Trial report in Bone marrow transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Neurologic complications after allogeneic transplantation: a meta-analysis.Annals of clinical and translational neurology · 2019Pooled it
- In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Bone marrow transplantation · 2017Pooled it
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Guideline
- Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Pharmacological Maintenance Therapies After Allogeneic Hematopoietic Cell Transplantation.Advances in experimental medicine and biology · 2025Review
- Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024Review
- Allogeneic stem cell transplantation in multiple myeloma: is there still a place?Frontiers in oncology · 2024Review
- Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.International journal of hematology · 2023Review
- Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.Oncology and therapy · 2022Review
- Review
- Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.Annals of hematology · 2021Article
- Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma.Bone marrow transplantation · 2021Article
- Prognostic Factors for Postrelapse Survival after ex Vivo CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression.Bone marrow transplantation · 2020Article
- Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.Clinical lymphoma, myeloma & leukemia · 2020Article
- The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?Haematologica · 2019Article
- Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.Haematologica · 2019Article
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Haematologica · 2018Review
- Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Cancer cell international · 2018Article
- Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.Hematology. American Society of Hematology. Education Program · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapse after dose-reduced allograft in advanced myeloma patients remains high. To reduce the risk of relapse, we investigated a myeloablative toxicity-reduced allograft (aSCT) consisting of i.v. BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months. The cumulative incidence of non-relapse mortality at 1 year was 6% (95% confidence interval (CI): 0-14). After a median interval of 168 days following aSCT, 24 patients started with a median dose of 5 mg (r, 5-15) lenalidomide without dexamethasone. During follow-up, 13 patients discontinued lenalidomide owing to progressive disease (n=6), GvHD (n=3), thrombocytopenia (n=2), or fatigue (n=2). Major toxicities of lenalidomide were GvHD II-III (28%), viral reactivation (16%), thrombocytopenia (III-IV°,16%), neutropenia (III/IV°, 8%), peripheral neuropathy (I/II°, 16%), or other infectious complication (8%). Cumulative incidence of relapse at 3 years was 42% (95% CI: 18-66). The 3-year estimated probability of PFS and OS was 52% (95% CI: 28-76) and 79% (95% CI: 63-95), respectively. Toxicity-reduced myeloablative allograft followed by lenalidomide maintenance is feasible and effective in relapsed patients with MM, but the induction of GvHD should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.